Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 3Genitourinary 2Thoracic 1Sarcoma 1Lymphoid 1Head & Neck 1Gynecologic 1Gastrointestinal 1CNS 1Breast 1

Conditions

Lymphoma, Non-Hodgkin 2Wilms Tumor 1Sarcoma, Ewing 1Ovarian Neoplasms 1Osteosarcoma 1Neuroblastoma 1Myelodysplastic Syndromes 1Multiple Myeloma 1Melanoma 1Lymphoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Hodgkin Disease 1Hepatoblastoma 1Endometrial Neoplasms 1Desmoid Tumors 1Colorectal Neoplasms 1Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 14Nivolumab 9Specimen Handling 4Magnetic Resonance Spectroscopy 4fludarabine 3atezolizumab 3Ipilimumab 3Drug Therapy 3Cyclophosphamide 3epacadostat 2entrectinib 2durvalumab 2X-Rays 2Sirolimus 2Radiotherapy 2Radiation 2Methods 2Interleukin-2 2Injections 2CTLA-4 Antigen 2Blood Specimen Collection 2Biopsy 2zimberelimab 1vocimagene amiretrorepvec 1varlilumab 1utomilumab 1ulixertinib 1tremelimumab 1trastuzumab biosimilar HLX02 1trametinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Melanoma × Absorptiometry, Photon × Lymphoid × Clear all
NCT04851119 2026-05-05

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Children's Oncology Group

Phase 1/2 Recruiting
147 enrolled
CNSDermatologicGastrointestinalGenitourinaryGynecologicLymphoidSarcoma

Carcinoma, Hepatocellular, Lymphoma, Non-Hodgkin, Melanoma, Wilms Tumor, Neuroblastoma, Ovarian Neoplasms, Sarcoma, Ewing, Osteosarcoma, Colorectal Neoplasms, Endometrial Neoplasms, Hepatoblastoma, Desmoid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡